Cramer’s lightning round: BioXcel Therapeutics may be home run or nothing

Business

Loading chart…

4D Molecular Therapeutics Inc: “Regeneron is the horse to bet on, because it’s been a great investment.”

Loading chart…

SoFi Technologies Inc: “I do believe it’s bottoming, but I don’t know what gets it higher.”

Loading chart…

BioXcel Therapeutics Inc: “It may be home run or nothing, and that’s always tough.”

Loading chart…

Veru Inc: “The test for [the company’s Covid treatment pill] … The FDA staff didn’t seem to like it.”

Jim Cramer’s Guide to Investing

Click here to download Jim Cramer’s Guide to Investing at no cost to help you build long-term wealth and invest smarter.

Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.

Disclaimer

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer TwitterFacebookInstagram

Questions, comments, suggestions for the “Mad Money” website? madcap@cnbc.com

Products You May Like

Articles You May Like

Jim Cramer says Meta Platforms’ latest quarter is why he stuck with the stock
Wait until age 70 to claim Social Security: ‘The return on being patient is huge,’ says economist
Gautam Adani calls off $2.5 billion equity sale as regulatory concerns grow
Stocks making the biggest moves premarket: McDonald’s, UPS, General Motors and more
States have $70 billion in unclaimed assets. How to check if any is yours

Leave a Reply

Your email address will not be published. Required fields are marked *